51
Participants
Start Date
March 31, 2012
Primary Completion Date
April 30, 2013
Study Completion Date
April 30, 2013
GS-7340
Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.
Tenofovir disoproxil fumarate
Subjects will receive 300mg of Tenofovir disoproxil fumarate (TDF) over 28 days of therapy
Auckland Clinical Studies, Auckland
Alfred Hospital, Melbourne
Austin Health, Melbourne
Linear Clinical Research Ltd, Nedlands
University of Maryland Institute of Human Virology, Baltimore
Henry Ford Health System, Detroit
Baylor College of Medicine - St. Luke's Episcopal Hospital, Houston
Research and Education Inc., San Diego
Monash Medical Centre, Melborne
Downtown Infectious Diseases Clinic (University of British Columbia), Vancouver
The Ottawa Hospital, General Campus, Ottawa
Toronto General Hospital, Toronto
Algorithme Pharma, Montreal
Pro-recherche, Saint Romuald
University Hospitals Birmingham NHS Foundation Trust, Birmingham
Grahame Hayton Unit, London
University College London Hospital, London
Institute of Liver Studies, King's College Hospital, London
Nottingham University Hospitals NHS Trust - Queens Medical Centre, Nottingham
Lead Sponsor
Gilead Sciences
INDUSTRY